

SUPPLEMENTARY INFORMATION:**A. Purpose**

The GSAR provision at 552.219–72 requires a contractor (except small business concerns) to submit a subcontracting plan when a negotiated acquisition including construction, repair, and alterations and lease contracts (except those solicitations using simplified procedures) meets all four of the following conditions.

1. When the contracting officer anticipates receiving individual subcontracting plans (not commercial plans).
2. When award is based on trade-offs among cost or price and technical and/or management factors under FAR 15.101–1.
3. The acquisition is not a commercial item acquisition.
4. The acquisition offers more than minimal subcontracting opportunities.

B. Annual Reporting Burden

Respondents: 1,020.

Responses per Respondent: 1.

Hours per Response: 12.

Total Burden Hours: 12,240.

Obtaining Copies of Proposals:

Requesters may obtain a copy of the information collection documents from the General Services Administration, Regulatory Secretariat (VPR), 1800 F Street, NW., Room 4041, Washington, DC 20405, telephone (202) 501–4755. Please cite OMB Control No. 3090–0252, Preparation, Submission, and Negotiation of Subcontracting Plans, in all correspondence.

Dated: May 12, 2009.

Al Matera,

Director, Office of Acquisition Policy.

[FR Doc. E9–11588 Filed 5–18–09; 8:45 am]

BILLING CODE 6820–61–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Office of the National Coordinator for Health Information Technology**

ACTION: Announcement of grant award.

Recipient: American Hospital Association.

Purpose of Award: ONC announces the award of a grant to the American Hospital Association to fund a supplement to the Association's national survey of hospitals that will measure the adoption and use of electronic health records by these providers.

Amount of Award: \$101,973.

Project Period: 12 months with option for four additional years of funding at the same level.

Justification for Exception to Competition: The American Hospital Association, has many years of experience conducting surveys with a high response rate across all United States hospitals.

Name and Address of Awarding Office Official: Marc Weisman, Executive Director, Office of the National Coordinator for Health Information Technology, Department of Health and Human Services, 200 Independence Avenue, SW., Washington DC 20201.

Dated: May 13, 2009.

Marc Weisman,

Executive Director, Office of the National Coordinator for Health Information Technology.

[FR Doc. E9–11672 Filed 5–18–09; 8:45 am]

BILLING CODE 4150–45–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**President's Advisory Council for Faith-based and Neighborhood Partnerships**

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the President's Advisory Council for Faith-based and Neighborhood Partnerships announces the following meetings:

Name: President's Advisory Council for Faith-based and Neighborhood Partnerships Council meetings

Times and Dates: Thursday, June 4th at 2 p.m. Eastern; and Tuesday, June 16th at 4 p.m. Eastern.

Place: Meetings will be held via conference call.

Status: Open to the public, limited only by the space available.

Purpose: The Council brings together leaders and experts in fields related to the work of faith-based and neighborhood organizations in order to: Identify best practices and successful modes of delivering social services; evaluate the need for improvements in the implementation and coordination of public policies relating to faith-based and other neighborhood organizations; and make recommendations for changes in policies, programs, and practices.

Contact Person for Additional Information: Mara Vanderslice, 202–205–2419, mara.vanderslice@hhs.gov.

Supplementary Information: The meetings will be held via conference call. There is limited capacity to join the call and will be listen-only mode. Please

contact Mara Vanderslice for more information about how to join the call.

Agenda: Topics to be discussed include updates from Council subcommittees on Reform of the Faith-based and Neighborhood Partnerships Office, Economic Recovery, Fatherhood and Healthy Families, Inter-religious Dialogue and Cooperation, Environment and Climate Change and Global Poverty and Development.

Dated: May 13, 2009.

Mara Vanderslice,

Special Assistant.

[FR Doc. E9–11610 Filed 5–18–09; 8:45 am]

BILLING CODE 4154–07–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**Food and Drug Administration**

[Docket No. FDA–2009–N–0211]

Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 92 new drug applications (NDAs) and 49 abbreviated new drug applications (ANDAs) from multiple applicants. The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

DATES: Effective: June 18, 2009.

FOR FURTHER INFORMATION CONTACT:

Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, rm. 6366, Silver Spring, MD 20993–0002, 301–796–3601.

SUPPLEMENTARY INFORMATION: The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their requests, waived their opportunity for a hearing.

Application No.	Drug	Applicant
NDA 6-403	Priscoline (tolazoline hydrochloride (HCl))	Novartis Pharmaceuticals Corp., One Health Plaza, East Hanover, NJ 07936-1080
NDA 8-303	Apresoline (hydralazine HCl)	Do.
NDA 9-087	Hydergine (ergoloid mesylates) Sublingual Tablets	Do.
NDA 9-509	Aramine (metaraminol bitartrate) Injection, 10 milligrams (mg)/milliliter (mL)	Merck & Co., Inc., UG2C-50, P.O. Box 1000, North Wales, PA 19454-1099
NDA 9-987	Delta-Cortef (prednisolone) Tablets	Pharmacia & Upjohn Co., c/o Pfizer, Inc., 235 East 42d St., New York, NY 10017
NDA 10-060	Florinef (fludrocortisone acetate) Tablets	King Pharmaceuticals, Inc., 501 5th St., Bristol, TN 37620
NDA 10-392	Atarax (hydroxyzine HCl) Tablets	Pfizer, Inc., 235 East 42d St., New York, NY 10017
NDA 10-485	Atarax (hydroxyzine HCl) Syrup	Roerig Pharmaceuticals, c/o Pfizer, Inc.
NDA 10-571	Compazine (prochlorperazine maleate) Tablets	GlaxoSmithKline, 1250 South Collegeville Rd., UP4110, Collegeville, PA 19426
NDA 10-611	Halotestin (fluoxymesterone) Tablets, 2 mg, 5 mg, and 10 mg	Pharmacia & Upjohn Co., c/o Pfizer, Inc.
NDA 10-686	Moderil (rescinnamine) Tablets, 0.25 mg and 0.5 mg	Pfizer, Inc.
NDA 10-742	Compazine (prochlorperazine edisylate) Injection	GlaxoSmithKline
NDA 10-976	Enovid/Enovid-E/Enovid-E 21 (norethynodrel and mestranol) Tablets	G.D. Searle LLC, c/o Pfizer, Inc.
NDA 11-000	Compazine (prochlorperazine maleate) Extended-Release Capsules	GlaxoSmithKline
NDA 11-111	Vistaril (hydroxyzine HCl) Injection	Pfizer, Inc.
NDA 11-127	Compazine (prochlorperazine) Suppositories	GlaxoSmithKline
NDA 11-188	Compazine (prochlorperazine edisylate) Syrup	Do.
NDA 11-556	Anturane (sulfipyrazone) Tablets and Capsules	Novartis Pharmaceuticals Corp.
NDA 11-635	Diupres (chlorothiazide and reserpine) Tablets	Merck & Co., Inc.
NDA 11-793	Esidrix (hydrochlorothiazide) Tablets	Novartis Pharmaceuticals Corp.
NDA 11-838	Tofranil (imipramine HCl) Injection	Do.
NDA 12-193	Ser-Ap-Es (reserpine, hydralazine HCl, and hydrochlorothiazide) Tablets	Do.
NDA 12-329	Ismelin (guanethidine monosulfate) Tablets	Do.
NDA 12-753	Torecan (thiethylperazine maleate) Tablets, 10 mg	Do.
NDA 12-754	Torecan (thiethylperazine maleate) Injection, 5 mg/mL	Do.
NDA 12-791	Hypertensin (angiotensin amide) Injection	Do.
NDA 12-845	Renese (polythiazide) Tablets, 1 mg, 2 mg, and 4 mg	Pfizer, Inc.
NDA 13-636	Renese-R (polythiazide and reserpine) Tablets, 2 mg/0.25 mg	Do.
NDA 15-500	Tolinase (tolazamide) Tablets	Pharmacia & Upjohn Co., c/o Pfizer, Inc.
NDA 16-029	Ovulen (ethynodiol diacetate and mestranol) Tablets	G.D. Searle LLC, c/o Pfizer, Inc.
NDA 16-126	Primatene (epinephrine bitartrate) Mist, 0.2 mg, and Bronitin (epinephrine bitartrate) Mist, 0.3 mg	Wyeth Consumer Healthcare, Five Giralda Farms, Madison, NJ 07940
NDA 16-635	Cyanocobalamin CO-57 Schilling Test Kit	Mallinckrodt Medical, c/o Mallinckrodt, Inc., 675 McDonnell Blvd., Hazelwood, MO 63042

Application No.	Drug	Applicant
NDA 16-705	Ovulen-28 (ethynodiol diacetate and mestranol) Tablets	G.D. Searle LLC, c/o Pfizer, Inc.
NDA 16-709	Ortho-Novum 1/50-28 (norethindrone and mestranol) Tablets	Ortho-McNeil-Janssen Pharmaceutical, Inc., c/o Johnson & Johnson Pharmaceutical Research & Development, LLC, 920 Rt. 202, P.O. Box 300, Raritan, NJ 08869
NDA 16-758	Navane (thiothixene HCl) Oral Concentrate	Pfizer, Inc.
NDA 16-834	Lithane (lithium carbonate) Tablets	Do.
NDA 16-904	Navane (thiothixene HCl) Injection	Do.
NDA 17-059	TechneColl (technetium Tc-99m sulfur colloid kit)	Mallinckrodt Medical, c/o Mallinckrodt, Inc.
NDA 17-247	Sanorex (mazindol) Tablets	Novartis Pharmaceuticals Corp.
NDA 17-476	Slow-K (potassium chloride) Extended-Release Tablets	Do.
NDA 17-543	Ludiomil (maprotiline HCl) Tablets, 25 mg, 50 mg, and 75 mg	Novartis Pharmaceuticals Corp.
NDA 17-551	Perchloracap (potassium perchlorate) Capsules	Mallinckrodt Medical, c/o Mallinckrodt, Inc.
NDA 17-842	TechneScan MAA (technetium Tc-99m albumin aggregate kit)	Do.
NDA 17-844	Radioiodinated Serum Albumin (Human) IHSA I-125 (iodinated I-125 albumin injection)	Do.
NDA 17-851	Lioresal (baclofen) Tablets, 10 mg and 20 mg	Novartis Pharmaceuticals Corp.
NDA 17-971	Eskalith (lithium carbonate) Tablets, 300 mg	JDS Pharmaceuticals, LLC, c/o Noven Pharmaceuticals, Inc., 11960 SW. 44th St., Miami, FL 33186
NDA 17-986	Minizide (prazosin HCl and polythiazide) Capsules, 1 mg, 2 mg, and 5 mg	Pfizer, Inc.
NDA 18-006	Meclomen (meclofenamate sodium) Capsules, 50 mg and 100 mg	Parke-Davis, a subsidiary of Pfizer, Inc.
NDA 18-152	Eskalith CR (lithium carbonate) Controlled-Release Tablets, 450 mg	JDS Pharmaceuticals, LLC, c/o Noven Pharmaceuticals, Inc.
NDA 18-202	Cytadren (aminoglutethimide) Tablets	Novartis Pharmaceuticals Corp.
NDA 18-245	Syntocinon (oxytocin) Injection	Do.
NDA 18-249	Sodium Lactate Injection USP	Hospira, Inc., 275 North Field Dr., Lake Forest, IL 60045-5046
NDA 18-272	Technescan Gluceptate (technetium Tc-99m gluceptate kit)	Draximage, a division of DRAXIS Specialty Pharmaceuticals, Inc., 16751 Autoroute TransCanada Highway, Kirkland, Qu. Canada H9H 4J4
NDA 18-285	Visken (prindolol) Tablets	Novartis Pharmaceuticals Corp.
NDA 18-535	Diulo (metolazone) Tablets, 2.5 mg, 5 mg, and 10 mg	G.D. Searle LLC, c/o Pfizer, Inc.
NDA 18-536	Xenon Xe-127 Gas	Mallinckrodt, Inc.
NDA 18-904	Urologic G (citric acid, sodium carbonate, and magnesium oxide) Irrigation in Plastic Containers	Hospira, Inc.
NDA 19-650	Flumadine (rimantadine HCl) Syrup	Forest Laboratories, Inc., Harborside Financial Center III, suite 602, Jersey City, NJ 07311
NDA 19-672	Efidac 24 Pseudoephedrine/Brompheniramine (pseudoephedrine HCl and brompheniramine maleate) Extended-Release Tablets	Alza Corp., 1900 Charleston Rd., P.O. Box 7210, Mountain View, CA 94039-7210
NDA 19-721	Norditropin (somatotropin recombinant) for Injection	Novo Nordisk Inc., 100 College Rd. West, Princeton, NJ 08540
NDA 19-746	Efidac 24 Chlorpheniramine (chlorpheniramine maleate) Extended-Release Tablets	Alza Corp.

Application No.	Drug	Applicant
NDA 19-753	Ethmozine (morizine HCl) Tablets	Shire Development, Inc., 725 Chesterbrook Blvd., Wayne, PA 19087
NDA 19-762	Testoderm (testosterone) and Testoderm with Adhesive	Alza Corp.
NDA 19-775	Minipress XL (prazosin HCl) Extended-Release Tablets	Pfizer, Inc.
NDA 19-794	Depakote CP (divalproex sodium) Delayed-Release Tablets	Abbott Laboratories, 200 Abbott Park Rd., Abbott Park, IL 60664-6157
NDA 19-863	Geref Diagnostic (sermorelin acetate) for Injection	EMD Serono, Inc., One Technology Dr., Rockland, MA 02370
NDA 19-983	Prostep (nicotine) Transdermal System, 11 mg/24 hour (h) and 22 mg/24 h	Aveva Drug Delivery Systems, Inc., 3250 Commerce Pkwy., Miramar, FL 33025
NDA 20-013	Maxaquin (lomefloxacin HCl) Tablets	Pharmacia & Upjohn Co., c/o Pfizer, Inc.
NDA 20-044	Exosurf Neonatal (colfosceril palmitate, cetyl alcohol, and tyloxapol) Powder for Suspension	GlaxoSmithKline, P.O. Box 13398, Five Moore Dr., Research Triangle Park, NC 27709-3398
NDA 20-087	Floxin (ofloxacin) Solution for Injection	Ortho-McNeil Pharmaceutical, Inc., c/o Johnson & Johnson Pharmaceutical Research & Development, LLC
NDA 20-137	Demadex (torsemide) Injection	Hoffman-La Roche, Inc., 340 Kingsland St., Nutley, NJ 07110-1199
NDA 20-144	Transderm-Nitro (nitroglycerin)	Novartis Pharmaceuticals Corp.
NDA 20-154	Videx (didanosine) Chewable Tablets	Bristol-Meyers Squibb, 5 Research Pkwy., Signature 91 Bldg., Wallingford, CA 06492
NDA 20-155	Videx (didanosine) Buffered Powder for Oral Solution	Do.
NDA 20-199	Hivid (zalcitabine) Tablets	Hoffman-La Roche, Inc.
NDA 20-250	Halfan (halofantrine HCl) Tablets	GlaxoSmithKline, One Franklin Plaza, P.O. Box 7929, Philadelphia, PA 19101-7929
NDA 20-306	Fludeoxyglucose F-18 Injection	Downstate Clinical PET Center—Methodist Medical Center of Illinois, 221 NE. Glen Oak Ave., Peoria, IL 61636-0002
NDA 20-443	Geref (sermorelin acetate) for Injection	EMD Serono, Inc.
NDA 20-545	Procanbid (procainamide HCl) Extended-Release Tablets, 500 mg and 1,000 mg	King Pharmaceuticals, Inc.
NDA 20-686	LumenHance (manganese chloride tetrahydrate) for Solution	Bracco Diagnostics Inc., 107 College Rd. East, Princeton, NJ 08540
NDA 20-773	SonoRX (simethicone coated cellulose) Suspension	Do.
NDA 20-791	Testoderm TTS (testosterone transdermal system), 5 mg/24 h	Alza Corp.
NDA 21-019	Compazine (prochlorperazine maleate) Extended-Release Capsules	GlaxoSmithKline, Collegeville, PA 19426
NDA 21-868	Exubera (insulin recombinant human) Inhalation Powder, 1 mg and 3 mg	Pfizer, Inc.
ANDA 40-092	Digoxin Injection USP, 0.1 mg/mL	Hospira, Inc.
NDA 50-109	Mithracin (plicamycin) Injection, 2.5 mg	Pfizer, Inc.
NDA 50-286	Terramycin (oxytetracycline HCl) Capsules	Do.
NDA 50-316	Lincocin (lincomycin HCl) Capsules, 250 mg and 500 mg	Pharmacia & Upjohn Co., c/o Pfizer, Inc.
NDA 50-461	Ancef (cefazolin) for Injection	SmithKline Beecham, d/b/a GlaxoSmithKline, Philadelphia, PA 19101-7929
NDA 50-529	Pediazole (erythromycin ethylsuccinate and sulfisoxazole acetyl) for Oral Suspension	Ross Products Division, Abbott Laboratories, 3300 Stelzer Rd., Columbus, OH 43219-3034

Application No.	Drug	Applicant
NDA 50-613	Cefobid (cefoperazone sodium) Injection	Pfizer, Inc.
NDA 50-667	Lorabid (loracarbef for oral suspension USP), 100 mg/5 mL and 200 mg/5 mL	King Pharmaceuticals, Inc.
NDA 50-763	Mitozytrex (mitomycin) for Injection, 5 mg/vial	SuperGen, Inc., 4140 Dublin Blvd., suite 200, Dublin, CA 94568
ANDA 61-014	Terramycin (oxytetracycline HCl) Ophthalmic Solution	Pfizer, Inc.
ANDA 61-229	Polysporin Ophthalmic Ointment (bacitracin zinc and polymyxin B sulfate ophthalmic ointment)	Monarch Pharmaceuticals, Inc. (a wholly-owned subsidiary of King Pharmaceuticals, Inc.), 501 5th St., Bristol, TN 37620
ANDA 64-099	Amikacin Sulfate Injection USP, 250 mg/mL	Hospira, Inc.
ANDA 70-252	Naloxone HCl Injection USP, 0.02 mg/mL	Do.
ANDA 70-253	Naloxone HCl Injection USP, 0.02 mg/mL	Do.
ANDA 71-166	Bupivacaine HCl and Epinephrine Injection USP	Do.
ANDA 71-169	Bupivacaine HCl and Epinephrine Injection USP	Do.
ANDA 71-171	Bupivacaine HCl and Epinephrine Injection USP	Do.
ANDA 73-685	Acilac (lactulose solution USP), 10 grams (g)/15 mL	Nostrum Laboratories, Inc., 1800 North Topping Ave., Kansas City, MO 64120
ANDA 73-686	Laxilose (lactulose solution USP), 10 g/15 mL	Do.
ANDA 74-083	Nitroglycerin in 5% Dextrose Injection, 0.1 mg/mL	Hospira, Inc.
ANDA 74-127	Atenolol Tablets USP, 50 mg and 100 mg	Nostrum Laboratories, Inc.
ANDA 74-337	Furosemide Injection USP, 10 mg/mL	Hospira, Inc.
ANDA 74-391	Diclofenac Sodium Delayed-Release Tablets USP, 25 mg, 50 mg, and 75 mg	Roxane Laboratories, Inc., 1809 Wilson Rd., P.O. Box 16532, Columbus, OH 43216-6532
ANDA 74-403	Dopamine HCl Injection USP, 40 mg/mL	Hospira, Inc.
ANDA 74-404	Atenolol and Chlorthalidone Tablets USP, 50 mg/25 mg and 100 mg/25 mg	Nostrum Laboratories, Inc.
ANDA 74-474	Pindolol Tablets USP, 5 mg and 10 mg	Do.
ANDA 74-740	Atracurium Besylate Injection USP, 10 mg/mL	Hospira, Inc.
ANDA 74-741	Atracurium Besylate Injection USP, 10 mg/mL	Do.
ANDA 75-088	Cromoptic (cromolyn sodium) Ophthalmic Solution, 4%	King Pharmaceuticals, Inc.
ANDA 75-162	Clozapine Tablets USP, 25 mg and 100 mg	Par Pharmaceutical, Inc., One Ram Ridge Rd., Spring Valley, NY 10977
ANDA 75-466	Doxazosin Mesylate Tablets, 1 mg, 2 mg, 4 mg, and 8 mg	Genpharm Inc., c/o Mylan Pharmaceuticals, Inc., 781 Chestnut Ridge Rd., P.O. Box 4310, Morgantown, WV 26504-4310
ANDA 75-558	Vecuronium Bromide for Injection, 4 mg/Ampul	Hospira, Inc.
ANDA 75-762	Ofloxacin Injection, 40 mg/mL	Bedford Laboratories, Division of Ben Venue Laboratories, Inc., 300 Northfield Rd., Bedford, OH 44146
ANDA 75-899	Fluvoxamine Maleate Tablets, 25 mg, 50 mg, and 100 mg	Synthon Pharmaceuticals, Inc., 9000 Development Dr., P.O. Box 110487, Research Triangle Park, NC 27709
ANDA 76-138	Ciprofloxacin HCl Tablets USP, 250 mg, 500 mg, and 750 mg	Nostrum Laboratories, Inc.
ANDA 76-213	Fluconazole Tablets, 50 mg, 100 mg, 150 mg, and 200 mg	Roxane Laboratories, Inc.
ANDA 76-270	Mirtazapine Tablets USP, 15 mg, 30 mg, and 45 mg	Do.

Application No.	Drug	Applicant
ANDA 76-476	Benazepril HCl Tablets, 5 mg, 10 mg, 20 mg, and 40 mg	Mylan Pharmaceuticals, Inc.
ANDA 76-489	Anagrelide HCl Capsules, 0.5 mg and 1 mg	Roxane Laboratories, Inc.
ANDA 77-249	Oxandrolone Tablets USP, 2.5 mg and 10 mg	Do.
ANDA 77-445	Polyethylene Glycol 3350 Powder for Oral Solution	Teva Pharmaceuticals USA, 1090 Horsham Rd., P.O. Box 1090, North Wales, PA 19454
ANDA 77-648	Zonisamide Capsules, 25 mg, 50 mg, and 100 mg	Roxane Laboratories, Inc.
ANDA 78-026	Paroxetine Tablets USP, 10 mg, 20 mg, 30 mg, and 40 mg	Do.
ANDA 81-008	Strifon Forte DSC (chlorzoxazone tablets USP), 500 mg	Ferndale Laboratories, 780 West 8th Mile Rd., Ferndale, MI 48220
ANDA 81-095	Acetaminophen, Aspirin, and Codeine Phosphate Capsules, 150 mg/180 mg/15 mg	Mikart, Inc., 1750 Chattahoochee Ave., Atlanta, GA 30318
ANDA 83-283	Isoproterenol HCl Injection USP, 0.02 mg/mL	Hospira, Inc.
ANDA 83-838	Promethazine HCl Injection USP	Do.
ANDA 84-074	Bethanechol Chloride Tablets USP, 25 mg	Lannett Co., Inc., 9000 State Rd., Philadelphia, PA 19136
ANDA 84-702	Bethanechol Chloride Tablets USP, 5 mg	Do.
ANDA 84-712	Bethanechol Chloride Tablets USP, 10 mg	Do.
ANDA 84-735	Apresazide (hydralazine HCl and hydrochlorothiazide) Capsules, 25 mg/25 mg	Novartis Pharmaceuticals Corp.
ANDA 84-810	Apresazide (hydralazine HCl and hydrochlorothiazide) Capsules, 50 mg/50 mg	Do.
ANDA 86-366	Acetaminophen and Codeine Phosphate Oral Solution USP, 120 mg/12 mg per 5 mL	Roxane Laboratories, Inc.
ANDA 87-563	Quibron-T/SR (theophylline) Extended-Release Tablets, 300 mg	Monarch Pharmaceuticals, Inc.
ANDA 88-126	Aminophylline Oral Solution USP, 105 mg/5 mL	Roxane Laboratories, Inc.
ANDA 88-656	Quibron-T (theophylline) Tablets, 300 mg	Monarch Pharmaceuticals, Inc.
ANDA 89-650	Lidocaine HCl and Epinephrine Injection USP	Hospira, Inc.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research, by the Commissioner of Food and Drugs, approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective June 18, 2009.

Dated: April 30, 2009.

Douglas C. Throckmorton,
Deputy Director, Center for Drug Evaluation and Research.

[FR Doc. E9-11628 Filed 5-18-09; 8:45 am]

BILLING CODE 4160-01-S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Submission for OMB Review; Comment Request

Title: Annual Survey of Refugees (Form ORR-9).

OMB No.: 0970-0033.

Description: The Annual Survey of Refugees collects information on the social and economic circumstances of a random sample of refugees, Amerasians, and entrants who arrived in the United States in the five years prior to the date

of the survey. The survey focuses on the refugees training, labor force participation, and welfare utilization rates. Dates are segmented by region of origin, State of resettlement, and number of months since arrival. From the responses, the Office of Refugee Resettlement reports on the economic adjustment of refugees to the American economy. These data are used by Congress in its annual deliberations for refugee admissions and funding and by program managers in formulating policies for the future direction of the Refugee Resettlement Program.

Respondents: Refugees, entrants, Amerasians, and Havana parolees.